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A continuous rise in life expectancy has led to an increase 
in the number of senior citizens, now amounting to a fifth 
of the global population, and to a dramatic increase in the 
prevalence of diseases of the elderly. This review discuss-
es the threat of dementia, a disease that imposes enor-
mous financial burden on health systems and warrants 
efficient therapeutic solutions. What we learned from nu-
merous failed clinical trials is that we have to immediately 
take into account two major elements: early detection of 
dementia, much before the onset of symptoms, and per-
sonalized (precision) medicine treatment approach. We 
also discuss some of the most promising therapeutic di-
rections, including stem cells, exosomes, electromagnetic 
fields, and ozone.
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World Health Organization (WHO) proclaimed 2020-2030 
“the decade of healthy aging” (1). By dedicating a whole 
decade to aging, the WHO wants to draw attention to the 
steep increase in human life expectancy in the last 100 
years and a huge challenge that this phenomenon pres-
ents for humanity. On average, every 10 years, life expec-
tancy increases for 2-4 years, which means that in 1950s 
the average life expectancy was 45 years, in 1980s 60 years, 
and now it is 75 years (2). The decade of healthy aging is 
our attempt to tackle the approaching problems: our plan-
et is changing dramatically, and the current proportion of 
the population above 60 years (17%) will double in only 
thirty to forty years. The fact that in the next 30 years every 
third person in the world will fall in the category of senior 
citizen urges the adoption of completely new strategies in 
medical, social, and technological fields (3).
Besides vascular diseases and two major causes of death 
– heart and brain ischemia – neurodegeneration with con-
sequent dementia presents a health condition with the 
most significant health burden. Alzheimer’s disease (AD) 
is a growing public health concern worldwide. In Europe, 
an estimated 10.5 million people live with dementia, and 
this number is expected to increase by 2050 to 18.7 mil-
lion. Since only coordinated action can stop such diseases, 
European countries united under the umbrella of the Euro-
pean Brain Council (EBC). The EBC gathers scientific societ-
ies, patient organizations, professional societies, and indus-
try partners. Its main mission is to promote brain research 
and all the activities that can bring benefits in this field. 
The major goal is to improve the lives of the estimated 179 
million Europeans living with brain diseases. EBC offers its 
expertise and networks to foster cooperation between its 
member organizations, promoting and improving coop-
eration among scientists and various stakeholders in the 
field, including industry and general society. Notably, EBC 
emphasizes the importance of raising awareness and en-
couraging education on the brain and the consequences 
of brain diseases.
DEMENTIA IS STILL NOT A SUFFICIENTLY RECOGNIZED 
THREAT
While other chronic diseases of the elderly mostly cause 
recognizable symptoms, pain, impairment, and discom-
fort, Alzheimer`s and other types of dementia are rarely 
correctly recognized by the general public owing to their 
specific symptoms. The Croatian Brain Council devel-
oped a questionnaire with only one question: “When 
entering mature years of your life, it is expected that 
you will face some health problems. Which of them are you 
scared the most?” On the top of the participants’ list there 
were various cancers (breast cancer for 66 participants, 
gastrointestinal cancers for 63, and lung cancer for 40) 
even though the majority of neoplastic diseases are nowa-
days successfully cured. Dementia was mentioned by only 
11 out of 200 participants despite the fact that it can have 
the most humiliating consequences for a human being 
and despite the lack of efficient drugs to treat its fully de-
veloped form. It was recognized as slightly less important 
than “joint problems” (16 participants) and slightly more 
important than “sexual impotence” (8 participants). This 
finding is in strong disagreement with the fact that, apart 
from dramatic gradual disintegration of the person, the fi-
nancial burden for the family is much higher than for any 
other human disease. Annual costs vary for different lev-
els of care and countries, but are still enormous: from the 
minimum of $ 5000 in Croatia to more than $ 120 000 in 
the USA (4). The EBC demonstrated that in Europe the total 
cost of brain diseases on a yearly basis amounted to € 900 
billion; for dementia only, the cost was € 22 000 per patient 
per year. When we know that the number of seniors will 
double in the next decades, when we know the number 
of caregivers dedicated to every case, and when we know 
that recent studies failed to offer new therapeutic options, 
it is obvious that the urgent action is needed.
EARLY DIAGNOSTICS AND PERSONALIZED APPROACH 
ARE THE KEY POINTS IN THE TREATMENT OF DEMENTIA
Thus far, the majority of clinical trials for new dementia 
drugs have failed. This can be attributed to the brain’s in-
nate complexity and a high level of individuality. Brain dis-
eases are multifactorial, with a very complex background 
and variable onset and progression. Moreover, the obvi-
ous symptoms usually appear only when the disease en-
ters the last stage of progression. Therefore, we recognize 
two major strategic directions for improving dementia 
treatment: 1) detection of the pathological process be-
fore the onset of symptoms and 2) personalized treatment 
approach (5). Personalized approach can be especially ef-
fective when it comes to modifying the following param-
eters: insulin resistance (6), increased homocysteine levels 
(7), lack of exercise (8), lack of sleep (9), and various toxic 
factors (10) (Table 1). These factors impair the function of 
a critical number of neurons, but in a very individualized 
way. A cheap but very effective way to treat neurodegen-
erative diseases may be intermittent fasting, ie, fasting reg-
imens with recurring fasting periods lasting 24-48 hours, 
and time-restricted feeding, which consists of daily fasting 
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periods lasting 12-20 hours (11). Thus, the adjustment of 
these parameters can successfully reverse cognitive de-
cline (12-15). Another strategy relies on repurposing the 
existing drugs for the therapy of neurodegenerative dis-
eases with a personalized twist. Trazodone hydrochloride, 
a licensed anti-depressant, and dibenzoylmethane, a sub-
stance found in licorice, restored protein synthesis rates in 
prion-diseased and tauopathy frontotemporal dementia 
mice with established disease (16). De Coco et al (17) have 
shown that aged mice treated with nucleoside reverse 
transcriptase inhibitor lamivudine had down-regulated in-
terferon 1 activation and age-associated inflammation in 
several tissues. Zhang et al (18) have shown that amyloid 
beta oligomer can hijack norepinephrine-elicited signaling 
through alpha adrenergic receptor 2A (α2AAR) to activate 
pathogenic glycogen synthase kinase 3 beta/tau cascade. 
α2AAR blockers, such as idazoxan, are already used for the 
treatment of other disorders, and repurposing these drugs 
could be a potentially effective, readily available strategy 
for AD treatment (18). The mutations of glucocerebrosi-
dase gene, GBA1, are the most important risk factor for Par-
kinson disease (PD) (19). In vitro and in vivo studies have 
reported that β-glucocerebrosidase enzyme activity can 
be increased, and α-synuclein levels reduced, by ambroxol 
(19). A recent non-randomized, non-controlled study has 
suggested that ambroxol therapy was safe and well toler-
ated and that ambroxol penetrated the blood brain barrier 
(BBB) well (19). Ambroxol is a promising treatment modal-
ity, but a placebo-controlled clinical trial is necessary to ex-
amine if it has any effect on the natural progression of PD. 
All these drugs show huge individual differences in every 
tested patient. Understanding the basis of this variability 
will help to improve the general efficacy of future thera-
peutic approaches.
Apart from personalized approach, here we stress the need 
for early diagnostics. Some molecules have already re-
vealed a clear benefit in the preclinical set up, while some 
are still entering clinical applications. Cerebrospinal fluid 
(CSF) biomarkers include amyloid β (Aβ42, Aβ42/40), to-
tal tau (T-tau), and phosphorylated tau (P-tau 181). These 
biomarkers have a high diagnostic accuracy in earlier dis-
ease stages. Many studies have shown that patients with 
Aβ have elevated levels of T-tau and P-tau protein and de-
creased levels of β-amyloid (20). Other most promising 
biomarkers in the CSF include TREM2, a transmembrane 
receptor that is expressed by microglia (21) and visine-like 
protein 1, a neuronal calcium-sensing protein that par-
ticipates in neuroprotection and neurotoxic processes in 
the brain. It is a marker of neural damage and it correlates 
well with T-tau and P-tau 181 (22). Neurogranin (NGRN) is 
a postsynaptic protein that is expressed mainly in the cor-
tical regions and is associated with cognition. Reduced 
NGRN levels are found in the cortex and hippocampal re-
gion of the brain, which are most affected by AD. NGRN 
can be used to predict the progression of cognitive def-
icit and can indicate the loss of synapses (23). The β-site 
of APP cleaving enzyme 1 (BACE-1) is a β-secretase that is 
important for the cleavage of APP protein, while the result-
ing peptides aggregate and form extracellular plaques. The 
levels of this enzyme are elevated in people with AD com-
pared with healthy controls and patients with other forms 
of dementia (24). Kallikrein-8 (KLK8) is a protease (neurop-
sin) up-regulated in the hippocampus of patients with ear-
ly dementia. Short-term KLK8 inhibition in moderate stage 
of the disease mitigated the features of Alzheimer (25).
The major obstacle in recognizing these biomarkers is their 
poor or not existing availability in blood. To overcome the 
need for CSF collection or other invasive and complex 
methods, several new concepts have been developed. 
Some of them are based on stem cell technology, which 
continues to offer new treatment options in biomedicine. 
Apart from being used in research (26) and in therapeu-
tic applications (27,28), stem cells also offer new possibili-
ties in early diagnostics. One of the most innovative ap-
proaches using stem cells is the “Check My Brain” platform, 
owned by Omnion Research International (29). It offers 
a simple procedure of transformation of hairs into neu-
rons, which provides three sets of information: 1) early 
diagnostics of brain diseases, by detecting biomark-
TABLE 1. Major promising strategies for the treatment of neu-
rodegenerative disorders
Repurposed drugs Reference
Trazodone hydrochloride and dibenzoylmethane  (16)
Lamivudine  (17)
Idazoxan  (18)
Ambroxol  (19)
Physiology-related parameters suitable for 
personalization
Insulin resistance  (6)
Vitamin B12 and homocysteine  (7)
Physical activity  (8)
Sleep  (9)
Intermittent fasting and time restricted feeding  (11)
Individualized multifactorial protocols  (12-15)
Exosomes  (37,38)
Electromagnetic fields  (39-51)
Ozone  (57)
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ers using cell cultures, 2) the prognosis of disease progres-
sion by assessing the changes in biomarkers levels, and 3) 
personalized instructions on dietary, supplementary, and 
other approaches that could bring benefit for the individu-
al brain cells. By combining disease detection much before 
the onset of visible symptoms and the individual-tailored 
approach, “Check My Brain” points the direction that is re-
quired in addressing the threat of neurodegenerative dis-
eases.
ExOSOMES AS A NEw TOOL AGAINST DEMENTIA
As much as aging is a natural process, diseases and impair-
ments occurring during its course are not. In Europe alone, 
it is expected that by 2050 the number of people living 
with dementia will increase by 43.85% – this imposes a 
large financial and health burden on modern society, war-
ranting the development of novel experimental approach-
es stemming from personalized therapy – one of the most 
prominent being extracellular vesicles.
Extracellular vesicles (EVs) are small, membranous par-
ticles released by cells. The most widely studied EVs are 
exosomes. They are derived from endosomes and mi-
crovesicles, which develop from outward budding of the 
plasma membrane (30). The contents of exosomes are 
closely associated with their parent cells and include di-
versified proteins, lipids, noncoding RNA (including cir-
cular RNA and microRNA [miRNA]), and other molecules 
that may transport the exosome contents to the neigh-
boring or more distant cells. Exosomes can contain up to 
11 261 proteins, 2375 mRNA, and 764 miRNA sequences 
(31). Since one of the major obstacles in brain diseases is 
BBB impermeability, exosomes offer a unique advantage 
over most other approaches: they easily cross the BBB and 
deliver RNA sequences (32). In the central nervous system, 
both neurons and neuroglial cells can secrete and release 
exosomes into the extracellular environment, suggesting 
a diversified and important functions of exosomes (33). 
Owing to the ability of EVs to transport cargo packaged 
by the originating cell, their role in the pathogenesis of 
neurological conditions, particularly neurodegenerative 
diseases associated with misfolded proteins, has become 
a growing area of interest.
Neurodegenerative diseases share a common mechanism 
by which distinct proteins become misfolded and depos-
ited in specific regions during the pathogenic process 
(34). After initiating factors appear within the cells, their 
delivery to the extracellular space is accelerated us-
ing exosomes as potential carriers. Since most tau proteins 
released into extracellular fluids are cut off from mid-region 
tau (35), it is interesting to hypothesize that a full-length 
tau needed for disease progression is indeed brought by 
exosomes. Moreover, in the plaques of patients with AD, 
amyloid β-peptide colocalizes with specific exosomal pro-
teins (such as Alix), indicating that amyloid β-peptide at 
least in some specific cases may be deposited over exo-
somes secreted from neural cells in AD (36).
In addition to being used as carriers, exosomes can also 
be used in the diagnostics of brain diseases. The detection 
of exosomes in body fluids is becoming a novel tool for 
improving diagnosis and monitoring the biological activity 
of pathological process before the manifestation of appar-
ent clinical symptoms. Indeed, toxic proteins present in the 
exosomes can be detected in the early stage of a variety of 
neurodegenerative diseases (37). On the other hand, when 
treatment is concerned, exosomes are potent messengers 
able to protect neurons from oxidative stress. Moreover, 
they could be used as an excellent vehicle for gene thera-
py, since when compared with viruses, nanoparticles, and 
liposomes, exosomes have better therapeutic effect, tar-
geting ability, low immune response, and safety (38).
ELECTROMAGNETIC FIELDS AND OZONE IN THE 
TREATMENT OF BRAIN DISEASES
Apart from oxidative stress, imbalance in calcium homeo-
stasis, and hormonal factors, AD is also characterized by 
inflammation and disorders of the cell cycle. These cause 
severe loss of neurons and synapses, as well as reactive gli-
osis, potentially altering the nature of innate electromag-
netic fields (EMF) around axons (39). Recently, in order to 
improve age-related physiological and pathological cogni-
tive impairments, different methods for non-invasive brain 
stimulation using electromagnetic fields have appeared. 
All of these therapies greatly rely on the main property of 
EMFs – the ability to influence charged cells and molecules 
in their vicinity.
After the success in treating anxiety and panic disorders, 
repetitive transcranial magnetic stimulation (rTMS) has re-
cently become the talking point in the AD treatment. This 
method uses an electric pulse generator and magnetic 
coil placed above the scalp to apply changing magnetic 
fields to the desired regions in order to, through electro-
magnetic induction, cause or increase electrical current 
flow through nerve cells (40). When it comes to AD specif-
ically, various studies have shown that rTMS is capable of 
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modulating cortical excitability and inducing long-lasting 
neuroplastic changes, even after the pulse application has 
ended (41-43)
Similar to rTMS, transcranial direct-current stimulation ap-
plies constant low direct current via electrodes to influ-
ence membrane depolarization (44), cause changes in 
N-methyl-D-aspartic receptors, and initiate long-term po-
tentiation-like mechanisms (45).
Other types of electromagnetic field therapy (EMF) are be-
ing investigated for their influence on various molecular 
mechanisms connected with the pathogenesis of AD, as 
well as innate electrical activity of the brain (46,47). One 
of these is deep brain stimulation, which uses implant-
ed neurostimulators, including electrodes, and a battery 
source within a titanium housing. It sends electrical im-
pulses to targeted regions in order to treat mostly move-
ment and depressive disorders, as well as chronic pain. 
However, nowadays, it is also increasingly being studied 
with respect to the treatment of AD-related memory im-
pairment (48,49).
Preclinical research is also being conducted on miRNA 
modulation using low frequency electromagnetic field (LF-
EMF). Since miRNAs regulate the expression of key proteins 
involved in the pathogenesis of AD, these studies show in-
teresting results in terms of the ability of LF-EMF to change 
miRNA expression (50). Through initiating miRNA-mediat-
ed epigenetic regulation, LF-EMF might be able to rebal-
ance the deregulated molecular pathways occurring in pa-
tients with AD. The main molecular mechanisms behind 
this process involve the reduction of β-secretase – sug-
gesting a protective function of the electromagnetic field, 
which would be contrary to the formation of amyloid beta 
(Aβ) – and an increased expression of miR-107, which is a 
negative regulator of BACE1 (50). Similarly, in mice mod-
els, radio frequency electromagnetic field has been shown 
to reduce the Aβ plaques and amyloid precursor protein 
(APP) in the whole brain, but its effect depended on the 
stage of AD (51).
However, electromagnetic field treatments are not the 
only innovative approaches in the field of AD diagnosis 
and therapy. Novel diagnostics and personalized detec-
tion techniques are being investigated, one of which is 
the use of continuous wave muon beams. Muons are a 
type of an elementary particle characterized as a lepton, 
carrying the same charge as an electron (−1 e) but with a 
half an integer spin. They are 207 times heavier than elec-
trons and can, therefore, penetrate deeper into the ob-
jects or tissue while maintaining a more uniform dose (52). 
Bossoni et al performed a muon spin rotation experiment 
in patients with AD, with an aim of probing the composi-
tion of the mineral core of ferritin, a cellular protein that 
stores iron (53). Since patients with AD often have altered 
composition of ferritin’s iron core, the authors investigat-
ed the structure of isolated ferritin proteins from a freshly 
frozen brain hemisphere of an AD patient and a healthy 
control. Interestingly, the ferritins isolated from the control 
patient contained a mineral compatible with ferrihydrite, 
while those isolated from the patient with AD contained a 
crystalline phase, possibly compatible with magnetite or 
maghemite. This additionally highlighted the importance 
of developing novel diagnostics and experimental tools 
for dementia research (53).
Another approach that has recently attracted attention is 
the therapeutic application of ozone. Ozone is a charged 
inorganic molecule that, through electrical activity, influ-
ences the phospholipids in the cell’s membrane, causing 
a downstream cascade of events. Different from classical 
single-molecule pharmacological principles, ozone gener-
ates a number of secondary compounds, which, in sub-
micromolar concentrations trigger a variety of reactions 
(54). Apart from being known for its applications as a dis-
infectant, ozone has strong immunomodulatory and heal-
ing effects, which allow its use to treat wounds and pain in 
oral medicine (55) and to influence immune reactions with 
effects linked to cytokines (56). Interestingly, both our un-
published data and the recently published data by anoth-
er group suggest that ozone variously influences nervous 
system cells (57). The most striking consequence of ozone 
application is its influence on APP accumulation, which im-
proves cognitive status of mice affected by AD (57).
In conclusion, here we presented a joint call for a wide 
recognition of dementia as one of the largest threats for 
the aging human society. There is a need for a truly coordi-
nated international action that will set up new standards: 
translation of innovative approaches for early diagnostic 
and personalized and precision therapy. Only in this way, 
we will enjoy the benefits of long human life and recog-
nize healthy aging as the basic human right.
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